Key result
Second BNT162b2 COVID-19 vaccine dose linked to acute myocarditis with sustained VT in young male.
Why the study?
Postvaccine myocarditis typically presents as self-limiting chest pain within a week after the second mRNA dose, but atypical presentations remain to be characterized.
Case Report (n=1)
No
Highlights a rare but severe presentation of post-COVID-19 mRNA vaccine myocarditis involving ventricular tachycardia and reduced LVEF.
Answers are grounded in this paper and cite their sources.
Clinicians should consider post-vaccine myocarditis in young males with new VT; this single case leaves open questions of incidence and causality.
To combat the coronavirus disease 2019 (COVID-19) pandemic, many countries have started population vaccination programs using messenger ribonucleic acid (mRNA) vaccines. With the widespread use of such vaccines, reports are emerging worldwide, of the vaccine's association with the development of myocarditis. Younger men are more likely to develop postvaccine myocarditis, which usually presents as self-limiting chest pain within a week after the second dose. We present a case of myocarditis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech), which presented late, with ventricular tachycardia (VT) reduced left ventricular ejection fraction (LVEF).
No takes yet. Share an insight, caveat, or question.
Lin et al. (2022) conducted a case report in Myocarditis complicated by ventricular tachycardia (n=1). tozinameran (BNT162b2) COVID-19 vaccine was evaluated. A 26-year-old male developed acute myocarditis complicated by sustained ventricular tachycardia 18 days after receiving his second dose of the tozinameran (BNT162b2) COVID-19 vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: